Meeting
2017 ASCO Annual Meeting
Oncological outcomes of intravesical gemcitabine and docetaxel for select patients with high grade recurrent NMIBC.
Authors
Niv Milbar
The James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, MD
Niv Milbar , Max Kates , Meera R. Chappidi , Mark P. Schoenberg , Trinity Bivalacqua
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Nonprostate) Cancer
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Bladder Cancer
Citation
J Clin Oncol 35, 2017 (suppl; abstr 4546)
DOI
10.1200/JCO.2017.35.15_suppl.4546
Abstract #
4546
Poster Bd #
224
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
Intravesical gemcitabine and docetaxel in the treatment of BCG-naïve non–muscle invasive urothelial carcinoma of the bladder: Updates from a phase 2 trial.
First Author: Sunil H. Patel
Poster
2022 ASCO Genitourinary Cancers Symposium
Long-term follow-up of intravesical gemcitabine and docetaxel as rescue therapy for nonmuscle-invasive bladder cancer.
First Author: Phani T. Chevuru
Poster
2022 ASCO Genitourinary Cancers Symposium
Sequential intravesical gemcitabine and docetaxel for BCG-naïve high-risk nonmuscle-invasive bladder cancer.
First Author: Ian Mitchell McElree
Poster
2019 Genitourinary Cancers Symposium
Sequential intravesical gemcitabine and docetaxel in the treatment of BCG-naive patients with non-muscle invasive bladder cancer.
First Author: Lewis Thomas